GleamWall
中文EN

NBP NovaBridge Biosciences

Pharmaceutical Preparations · Nasdaq · SEC CIK 1778016 · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY140.7%
TTM net income YoY44.0%
TTM EPS YoY44.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-11,395.1%
Net margin-32,868.5%
FCF margin-11,528.6%
EBITDA margin-11,319.9%

Returns

ROE-62.9%
ROA-43.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets34.2%
Debt / equity0.00x
Current ratio5.67x
Interest coverage-706.05x

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-28.1%
Payout ratio—
Capex / revenue25.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q4*2025-12-31 · USD2025Q3*2025-09-30 · USD2024Q4*2024-12-31 · USD2024Q3*2024-09-30 · USD2020Q4*2020-12-31 · CNY2019Q4*2019-12-31 · CNY
Income statement
Revenue—————0
R&D expense$55.66M$3.18M$6.03M$4.47M286.23M262.04M
SG&A expense$17.24M$5.81M$7.34M$7.94M91.63M71.82M
Operating income-$72.90M-$8.99M-$13.37M-$12.41M——
Interest expense————0525,000
Pretax income-$72.86M-$6.83M-$10.84M-$20.49M1.05B-348.57M
Income tax$0$0$0$012.23M—
Net income-$30.79M-$6.83M-$10.84M-$20.49M1.04B-348.57M
EBITDA-$72.89M-$8.97M-$13.31M-$12.39M——
EPS (diluted)——————
Balance sheet
Cash & equivalents$210.63M$228.06M$68.26M$79.33M4.76B1.19B
Short-term investments$210,000$210,000$105.14M—31.53M32.00M
Receivables————130.50M—
Inventory————0—
Current assets$217.52M$232.78M$176.69M—5.34B1.36B
PP&E, net$140,000$155,000$201,000—25.27M30.07M
Goodwill————162.57M162.57M
Intangibles————120.44M148.84M
Total assets$260.52M$277.41M$212.68M—6.33B1.74B
Current liabilities$26.89M$16.09M$8.45M—576.12M588.48M
Short-term debt—————50.00M
Total liabilities$29.58M$18.50M$11.52M—706.65M668.09M
Shareholders' equity$230.94M$258.92M$201.16M$219.74M5.63B-2.03B
Shares outstanding265.38M265.17M187.45M—164.89M8.36M
Cash flow statement
Operating cash flow-$14.60M$1.84M-$10.95M$8.42M1.02B-215.99M
Capital expenditure$0$0$38,000$1,0003.25M7.62M
Free cash flow-$14.60M$1.84M-$10.99M$8.42M1.01B-223.61M
Investing cash flow$0$0-$109,000-$81.66M54.48M77.33M
Financing cash flow-$3.02M—$0$0844.79M113.30M
Depreciation & amortization$15,000$17,000$61,000$20,0005.00M3.00M
Stock-based compensation$3.94M$1.46M$824,000$318,000100.89M10,000

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.